Key PSMA-Targeting RNT Combination Studies
| Combination strategy | Trial | Setting | Treatment | Phase |
|---|---|---|---|---|
| RNT plus immune checkpoint inhibitor | NCT03805594 | mCRPC; PSMA PET–positive at 3 or more metastatic sites; prior treatment with NAAT; no prior chemotherapy, except in HSPC setting | 177Lu-PSMA-617 and pembrolizumab | 1 |
| NCT03658447 (PRINCE) | mCRPC; prior treatment with NAAT; prior docetaxel permitted | 177Lu-PSMA-617 and pembrolizumab | 1/2 | |
| RNT plus radiosensitizer | NCT03511664 (LuPIN) | mCRPC; prior treatment with taxane and NAAT | 177Lu-PSMA-617 and idronoxil | 1/2 |
| RNT plus PARP inhibitor | NCT03874884 (LuPARP) | mCRPC; prior treatment with NAAT and taxane chemotherapy | 177Lu-PSMA-617 plus olaparib | 1 |
| RNT plus novel antiandrogen therapy | NCT04419402 (ENZA-p) | mCRPC with PSMA-positive disease; no prior chemotherapy, except in HSPC setting | 177Lu-PSMA-617 plus enzalutamide vs. enzalutamide | 2 |
NAAT = novel antiandrogen; HSPC = hormone-sensitive prostate cancer.